Lantern Pharma (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company, announced that it will host a live webinar on September 23 at 12:30 p.m. Eastern to present the business model, development roadmap and value proposition of Open-Medicine AI (“OMAI”), its wholly owned subsidiary. The webinar, led by Panna Sharma, founder and CEO of Open-Medicine AI, will detail OMAI’s multi-agentic AI platform for end-to-end therapeutic development, its expansion beyond rare cancers into additional disease categories and therapeutic modalities, and its planned subscription and enterprise licensing business model.
The announcement signals a strategic move by Lantern Pharma to monetize its artificial intelligence capabilities beyond internal drug development. By establishing OMAI as a separate entity with a subscription-based model, Lantern aims to create a recurring revenue stream while accelerating the adoption of AI-driven approaches across the biopharma industry. The webinar serves as a platform to attract potential partners and investors, underscoring the growing importance of AI in drug discovery and development.
Lantern Pharma’s core technology, the RADR artificial intelligence and machine-learning platform, integrates large-scale genomic and biological data to transform the cost, pace, and precision of oncology drug development. RADR identifies patients most likely to benefit from therapies and guides biomarker-driven clinical development. The company’s pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI.
The expansion of OMAI beyond rare cancers into additional disease categories could significantly broaden Lantern’s addressable market. By offering its AI platform as a service, Lantern may enable other biopharma companies to expedite their own drug development processes, potentially leading to more efficient and cost-effective therapies. This aligns with industry trends where AI is increasingly seen as a key enabler of precision medicine.
Investors and industry observers will be keen to learn more about OMAI’s platform architecture and its ability to scale across therapeutic modalities. The subscription and enterprise licensing model could provide a predictable revenue stream, which is often attractive to investors in the volatile biotech sector. However, the success of this model will depend on the platform’s proven efficacy and adoption by pharmaceutical partners.
The webinar is scheduled for September 23 at 12:30 p.m. Eastern. For more details, the full press release is available at https://ibn.fm/U9lmNA. Additionally, the latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN.
BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors, is part of the Dynamic Brand Portfolio @ IBN. It provides access to a vast network of wire solutions, article and editorial syndication to over 5,000 outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. For more information, visit https://www.BioMedWire.com. Full terms of use and disclaimers are available at https://www.BioMedWire.com/Disclaimer.
